Our systematic review reports on 5701 advanced/locally unresectable or metastatic BC samples tested for PIK3CA mutation, primarily derived from retrospective analyses of tissue from archived samples, acquired as a part of observational or clinical trials. The gene discussed is PIK3CA; the disease is breast cancer.